In Abivax's trial, placebo patients dropped out due to lack of efficacy, meaning they were monitored for less time than patients on the effective drug. This "adverse event capture" bias can falsely make the drug arm appear to have a higher rate of side effects, a subtle but critical data interpretation error.

With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

Real-world data for pemigatinib in cholangiocarcinoma showed a higher response rate (59%) than the pivotal FITE-202 trial (36%). This discrepancy likely stems from the lack of standardized, centrally reviewed imaging in real-world settings, which can inflate perceived response. Comparable progression-free survival across both settings supports this interpretation.

Despite statistically significant results, Akiso's successful China-only study faced skepticism due to its trial design. Exclusions of older patients and those with high bleeding risk cast doubt on whether the positive findings can be replicated in a diverse global population, posing a barrier to wider acceptance.

By enrolling more participants, Chinese clinical trials achieve greater statistical power. This reduces the likelihood of both Type 1 (false positive) and Type 2 (false negative) errors, leading to more reliable data and a lower chance of abandoning a truly effective drug.

The phase 3 trial for luspatercept narrowly missed its primary endpoint because of an unusually high placebo response in the Asia-Pacific region, especially China. After a single patient's data was re-adjudicated, the p-value became significant, highlighting how operational factors and regional practices can mask a drug's true efficacy in global trials.

The debate over Summit's Ivanecimab lung cancer data from its China-based Harmony 6 trial shows the risk of assuming data is globally applicable. Differences in patient populations, such as smoking history in squamous cell carcinoma, can make clinical results from one region non-translatable to another, posing a major challenge for global drug developers.

The FDA is requiring higher US patient enrollment in global trials to address concerns that results from predominantly non-US populations (e.g., Asia) may not be generalizable. This reflects worries about differences in prior standard-of-care treatments and potential pharmacogenomic variations affecting outcomes.